Literature DB >> 17727302

Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment.

Deana Lazaro1.   

Abstract

Systemic lupus erythematosus is an autoimmune multi-system disease of uncertain aetiology with highly variable clinical manifestations. Women of child-bearing age are most often affected; however, approximately 10-20% of cases occur in older patients. Elderly-onset lupus has been defined in various studies as onset of lupus after age 50-65 years. Menopause and changes in cellular immunity with aging may contribute to development of lupus in older adults. Many studies suggest that the clinical and serological features of elderly-onset lupus differ from those of lupus in younger patients. Arthritis, fever, serositis, sicca symptoms, Raynaud's syndrome, lung disease and neuropsychiatric symptoms are more common in patients with elderly-onset lupus, while malar rash, discoid lupus and glomerulonephritis are less common in elderly-onset patients compared with younger lupus patients. Most elderly-onset lupus patients have a positive anti-nuclear antibody test, but the prevalence of anti-double-stranded DNA and hypocomplementaemia is lower in elderly-onset patients than in younger patients. Rheumatoid factor, anti-Ro/Sjögren's syndrome (SS) A and anti-La/SSB are more often positive in elderly-onset patients. The diagnosis of elderly-onset lupus may be delayed for many months: insidious onset, low prevalence and similarity to other more common disorders make the diagnosis of lupus challenging in this population. Treatment of lupus in the elderly may be complicated by co-morbidities and increased risk of toxicities from usual treatments. Optimal management of elderly-onset lupus is empiric because of a lack of randomised controlled studies. However, the approach to treatment is similar regardless of the age of the patient. This article discusses the prevalence, clinical course, serological features, prognosis and treatment of elderly-onset systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17727302     DOI: 10.2165/00002512-200724090-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  92 in total

1.  Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.

Authors:  R J Stevens; C Andujar; C J Edwards; P R Ames; A R Barwick; M A Khamashta; G R Hughes
Journal:  Br J Rheumatol       Date:  1997-03

2.  Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.

Authors:  Frédéric A Houssiau; Carlos Vasconcelos; David D'Cruz; Gian Domenico Sebastiani; Enrique de Ramon Garrido; Maria Giovanna Danieli; Daniel Abramovicz; Daniel Blockmans; Alessandro Mathieu; Haner Direskeneli; Mauro Galeazzi; Ahmet Gül; Yair Levy; Peter Petera; Rajko Popovic; Radmila Petrovic; Renato Alberto Sinico; Roberto Cattaneo; Josep Font; Geneviève Depresseux; Jean-Pierre Cosyns; Ricard Cervera
Journal:  Arthritis Rheum       Date:  2004-12

3.  B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

Authors:  M J Leandro; G Cambridge; J C Edwards; M R Ehrenstein; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2005-09-27       Impact factor: 7.580

4.  Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.

Authors:  R F van Vollenhoven; L M Morabito; E G Engleman; J L McGuire
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

5.  Systemic lupus erythematosus in the elderly.

Authors:  B S Foad; R P Sheon; A B Kirsner
Journal:  Arch Intern Med       Date:  1972-11

6.  Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus.

Authors:  K P Kyriakis; G J Kontochristopoulos; D N Panteleos
Journal:  Int J Dermatol       Date:  2000-03       Impact factor: 2.736

7.  Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus.

Authors:  Y Nancy You; Ayalew Tefferi; David M Nagorney
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

8.  Systemic lupus erythematosus in the elderly: clinical and immunological characteristics.

Authors:  J Font; L Pallarés; R Cervera; A López-Soto; M Navarro; X Bosch; M Ingelmo
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

9.  Anticardiolipin antibody associated ischaemic strokes in elderly patients without systemic lupus erythematosus.

Authors:  K K Chakravarty; A H Al-Hillawi; M A Byron; C J Durkin
Journal:  Age Ageing       Date:  1990-03       Impact factor: 10.668

Review 10.  Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly.

Authors:  M Ramos-Casals; M García-Carrasco; M P Brito; A López-Soto; J Font
Journal:  Lupus       Date:  2003       Impact factor: 2.911

View more
  13 in total

1.  Age of onset influences on clinical and laboratory profile of patients with systemic lupus erythematosus.

Authors:  Rafael Hennemann Sassi; Jordana Vaz Hendler; Giovana Fagundes Piccoli; Andrese Aline Gasparin; Rafael Mendonça da Silva Chakr; João Carlos Tavares Brenol; Odirlei André Monticielo
Journal:  Clin Rheumatol       Date:  2016-11-17       Impact factor: 2.980

Review 2.  A case of very late-onset systemic lupus erythematosus and updated pooled analysis of late-onset cases in the literature.

Authors:  Fang Chen; Lu Zhang; Guochun Wang; Bing Lin; Liying Wang
Journal:  Rheumatol Int       Date:  2011-09-07       Impact factor: 2.631

Review 3.  Menopause and Rheumatic Disease.

Authors:  Mitali Talsania; Robert Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2017-05       Impact factor: 2.670

4.  Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity.

Authors:  Lingyan Chen; Yong-Fei Wang; Lu Liu; Adrianna Bielowka; Rahell Ahmed; Huoru Zhang; Phil Tombleson; Amy L Roberts; Christopher A Odhams; Deborah S Cunninghame Graham; Xuejun Zhang; Wanling Yang; Timothy J Vyse; David L Morris
Journal:  Hum Mol Genet       Date:  2020-06-27       Impact factor: 6.150

Review 5.  Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role.

Authors:  Maryam Al Hussaini; Emad I Hammouda; Ahmed E Hammouda
Journal:  Int J Clin Pharm       Date:  2014-07-02

6.  Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis.

Authors:  C J Poulton; P H Nachman; Y Hu; J G McGregor; J C Jennette; R J Falk; S L Hogan
Journal:  Clin Exp Rheumatol       Date:  2013-01-23       Impact factor: 4.473

7.  Survival analysis of late-onset systemic lupus erythematosus: a cohort study in China.

Authors:  Hui Lin; James Cheng-chung Wei; Chun-yu Tan; Yuan-yuan Liu; Yan-hong Li; Feng-xia Li; Dai-hua Deng; Bing Yan; Yi Liu; Yi Zhao
Journal:  Clin Rheumatol       Date:  2012-09-15       Impact factor: 2.980

8.  Late-onset systemic lupus erythematosus: clinical features, course, and prognosis.

Authors:  Aleksandra Tomic-Lucic; Radmila Petrovic; Marija Radak-Perovic; Dragan Milovanovic; Jasmina Milovanovic; Sandra Zivanovic; Suzana Pantovic; Mirjana Veselinovic
Journal:  Clin Rheumatol       Date:  2013-03-21       Impact factor: 2.980

9.  Clinical expression and course in patients with late onset systemic lupus erythematosus.

Authors:  S Stefanidou; C Gerodimos; A Benos; V Galanopoulou; I Chatziyannis; F Kanakoudi; S Aslanidis; P Boura; T Sfetsios; L Settas; M Katsounaros; D Papadopoulou; P Giamalis; N Dombros; M Chatzistilianou; A Garyfallos
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

10.  [Primitive Sjögren syndrome in the elderly: clinical and immunological characteristics].

Authors:  Wafa Chebbi; Wafa Ben Salem; Rim Klii; Wassia Kessomtini; Saida Jerbi; Mohamed Habib Sfar
Journal:  Pan Afr Med J       Date:  2015-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.